BR0215156A - Cis-imidazolinas como inibidores de mdm 2 - Google Patents

Cis-imidazolinas como inibidores de mdm 2

Info

Publication number
BR0215156A
BR0215156A BR0215156-1A BR0215156A BR0215156A BR 0215156 A BR0215156 A BR 0215156A BR 0215156 A BR0215156 A BR 0215156A BR 0215156 A BR0215156 A BR 0215156A
Authority
BR
Brazil
Prior art keywords
mdm
cis
inhibitors
imidazolines
formula
Prior art date
Application number
BR0215156-1A
Other languages
English (en)
Inventor
Norman Kong
Emily Aijun Liu
Binh Thanh Vu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0215156A publication Critical patent/BR0215156A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"CIS-IMIDAZOLINAS COMO INIBIDORES DE MDM 2". A presente invenção refere-se a compostos de acordo com a fórmula I e fórmula II e seus sais e ésteres farmaceuticamente aceitáveis, contendo as designações fornecidas aí e que inibem a interação de proteína MDM2 com peptídeo semelhante a p53 e tem atividade antiproliferativa (I) (II).
BR0215156-1A 2001-12-18 2002-12-09 Cis-imidazolinas como inibidores de mdm 2 BR0215156A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34172901P 2001-12-18 2001-12-18
US39087602P 2002-06-21 2002-06-21
PCT/EP2002/013905 WO2003051360A1 (en) 2001-12-18 2002-12-09 Cis-imidazolines as mdm2 inhibitors

Publications (1)

Publication Number Publication Date
BR0215156A true BR0215156A (pt) 2004-10-19

Family

ID=26992633

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0215156-1A BR0215156A (pt) 2001-12-18 2002-12-09 Cis-imidazolinas como inibidores de mdm 2

Country Status (20)

Country Link
US (1) US6617346B1 (pt)
EP (1) EP1463501B1 (pt)
JP (1) JP4361798B2 (pt)
KR (1) KR100640707B1 (pt)
CN (1) CN1604778A (pt)
AR (1) AR037882A1 (pt)
AT (1) ATE397925T1 (pt)
AU (1) AU2002361986B2 (pt)
BR (1) BR0215156A (pt)
CA (1) CA2468783A1 (pt)
DE (1) DE60227108D1 (pt)
ES (1) ES2307822T3 (pt)
MX (1) MXPA04005880A (pt)
PA (1) PA8561801A1 (pt)
PE (1) PE20030717A1 (pt)
PL (1) PL370909A1 (pt)
RU (1) RU2312101C2 (pt)
TW (1) TW200301696A (pt)
UY (1) UY27586A1 (pt)
WO (1) WO2003051360A1 (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004253245B2 (en) * 2003-06-17 2010-02-11 F. Hoffmann-La Roche Ag CIS-imidazolines as MDM2 inhibitors
US7132421B2 (en) 2003-06-17 2006-11-07 Hoffmann-La Roche Inc. CIS-imidazoles
JP4814228B2 (ja) * 2004-05-18 2011-11-16 エフ．ホフマン−ラ ロシュ アーゲー 新規ｃｉｓ−イミダゾリン
EP1758579A1 (en) * 2004-05-29 2007-03-07 7TM Pharma A/S Crth2 receptor ligands for medicinal uses
US7893278B2 (en) * 2004-06-17 2011-02-22 Hoffman-La Roche Inc. CIS-imidazolines
KR100944301B1 (ko) * 2005-02-22 2010-02-24 더 리젠츠 오브 더 유니버시티 오브 미시간 Ｍｄｍ２의 소분자 억제제 및 이의 용도
US7759383B2 (en) 2005-02-22 2010-07-20 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
JP4870778B2 (ja) 2005-12-01 2012-02-08 エフ．ホフマン−ラ ロシュ アーゲー 抗ガン剤として使用されるｐ５３およびｍｄｍ２タンパク質間の相互作用の阻害剤としての２，４，５−トリフェニルイミダゾリン誘導体
KR101015073B1 (ko) * 2006-01-18 2011-02-16 에프. 호프만-라 로슈 아게 Ｍｄｍ2 억제제로서의시스-4,5-비아릴-2-헤테로시클릭-이미다졸린
US8470785B2 (en) 2006-07-28 2013-06-25 St. Jude Children's Research Hospital Method for treating ocular cancer
WO2008014216A1 (en) 2006-07-28 2008-01-31 St. Jude Children's Research Hospital Method for treating ocular cancer
US8222288B2 (en) 2006-08-30 2012-07-17 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
AU2007332493A1 (en) 2006-12-14 2008-06-19 Daiichi Sankyo Company, Limited Imidazothiazole derivatives
US7625895B2 (en) * 2007-04-12 2009-12-01 Hoffmann-Le Roche Inc. Diphenyl-dihydro-imidazopyridinones
RU2487127C2 (ru) * 2007-10-09 2013-07-10 Ф.Хоффманн-Ля Рош Аг Хиральные цис-имидазолины
EP2224961A1 (en) * 2007-11-26 2010-09-08 The Research Foundation of the State University of New York Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
WO2009151069A1 (ja) 2008-06-12 2009-12-17 第一三共株式会社 ４，７－ジアザスピロ［２．５］オクタン環構造を有するイミダゾチアゾール誘導体
PL2380892T3 (pl) 2009-01-16 2014-08-29 Daiichi Sankyo Co Ltd Pochodna imidazotiazolowa mająca strukturę pierścienia proliny
UA107814C2 (uk) 2009-11-12 2015-02-25 Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган Спірооксіндольні антагоністи мdм2
US10159669B2 (en) * 2010-03-02 2018-12-25 Ian H. Chan Individual and combination of mdivi-1 and nutlin-3 for topical or intravitreal ophthalmic use
WO2012047587A2 (en) * 2010-09-27 2012-04-12 Serrata, Llc Mdm2 inhibitors for treatment of ocular conditions
WO2012045018A1 (en) 2010-09-30 2012-04-05 St. Jude Children's Research Hospital Aryl-substituted imidazoles
FR2967072B1 (fr) 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
JP2014500870A (ja) 2010-11-12 2014-01-16 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン スピロ−オキシインドールｍｄｍ２アンタゴニスト
SG193002A1 (en) 2011-03-10 2013-09-30 Daiichi Sankyo Co Ltd Dispiropyrrolidine derivative
WO2012155066A2 (en) 2011-05-11 2012-11-15 Shaomeng Wang Spiro-oxindole mdm2 antagonists
KR101384683B1 (ko) * 2011-10-27 2014-04-11 한국생명공학연구원 ｍｄｍ２－결합 모티프를 포함하는 펩타이드 및 이의 용도
US9937178B2 (en) 2011-12-07 2018-04-10 Duke University Methods of identifying and using MDM2 inhibitors
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
KR102196882B1 (ko) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Hdm2 억제제로서의 치환된 이미다조피리딘
IL286427B2 (en) 2014-01-28 2024-08-01 Mayo Found Medical Education & Res Inhibitors bcl-2 anti-apoptotic protein family members for treatment of non cancer pulmonary disease or an opthalmic disease
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
TWI750129B (zh) * 2015-08-03 2021-12-21 瑞士商諾華公司 作為血液學毒性生物標記之ｇｄｆ-１５
SG11201808728QA (en) 2016-04-06 2018-11-29 Univ Michigan Regents Mdm2 protein degraders
US10759808B2 (en) 2016-04-06 2020-09-01 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
CN118436801A (zh) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
CN110088081A (zh) 2017-06-16 2019-08-02 尤尼蒂生物技术公司 制备用于药物用途的对映纯顺式-咪唑啉化合物的合成方法
US12239720B2 (en) 2018-04-06 2025-03-04 Oncolyze, Inc. Compositions for use in lysis of selective cancer cells
CN112912143A (zh) 2018-10-08 2021-06-04 美国密歇根州立大学试剂中心 小分子mdm2蛋白降解剂
KR20230005160A (ko) 2020-03-19 2023-01-09 카이메라 쎄라퓨틱스 인코포레이티드 Mdm2 분해제 및 이의 용도
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR75287B (pt) * 1980-07-25 1984-07-13 Ciba Geigy Ag
JPH02101065A (ja) * 1988-10-06 1990-04-12 Tanabe Seiyaku Co Ltd イミダゾリン誘導体及びその製法
US5474998A (en) 1990-08-17 1995-12-12 E. I. Du Pont De Nemours And Company Arthropodicidal pyrazolines, pyrazolidines and hydrazines
GB2351082A (en) * 1999-06-18 2000-12-20 Lilly Forschung Gmbh Synthesis of Cyclic Substituted Amidines

Also Published As

Publication number Publication date
KR20040068289A (ko) 2004-07-30
WO2003051360A1 (en) 2003-06-26
ATE397925T1 (de) 2008-07-15
MXPA04005880A (es) 2004-09-13
RU2004122404A (ru) 2005-05-27
EP1463501B1 (en) 2008-06-11
EP1463501A1 (en) 2004-10-06
JP4361798B2 (ja) 2009-11-11
CN1604778A (zh) 2005-04-06
DE60227108D1 (de) 2008-07-24
UY27586A1 (es) 2003-06-30
RU2312101C2 (ru) 2007-12-10
JP2005515210A (ja) 2005-05-26
KR100640707B1 (ko) 2006-10-31
AR037882A1 (es) 2004-12-09
ES2307822T3 (es) 2008-12-01
AU2002361986A1 (en) 2003-06-30
CA2468783A1 (en) 2003-06-26
TW200301696A (en) 2003-07-16
PA8561801A1 (es) 2003-07-28
PL370909A1 (en) 2005-05-30
US6617346B1 (en) 2003-09-09
PE20030717A1 (es) 2003-08-28
AU2002361986B2 (en) 2008-04-10

Similar Documents

Publication Publication Date Title
BR0215156A (pt) Cis-imidazolinas como inibidores de mdm 2
PA8561901A1 (es) Cis-imidazolinas
BR0205890A (pt) Pirazolopirimidinas como agentes terapêuticos
BR0205889A (pt) Pirazolopirimidinas como agentes tepapêuticos
DE69919397D1 (de) Thrombin-inhibitoren
TR199902606T2 (xx) Farnesil transferaz� engelleyici kinazolinonlar.
BR0115452A (pt) Compostos tendo atividade fungicida e processos para fabricação e uso dos mesmos
ECSP034850A (es) Sal citrato de 5, 8, 14-triazatetraciclo [10.3.1.02,11.04,9] hexadeca-2 (11),3,5,7,9-pentaeno y composiciones farmaceuticas de la misma
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
BR0108610A (pt) Compostos azapolicìclicos condensados com arila
BR0001468A (pt) ácidos dioxiciclopentil hidroxânicos
BR0114252A (pt) Derivados de nitrosodifenilamina
BR0109836A (pt) Processo de sìntese de perindopril e de seus sais farmaceuticamente aceitáveis
BR0212069A (pt) Agentes antidiabéticos orais
BR0014651A (pt) Inibidores de adesão de célula mediada por "alfa" l beta2
BR0210531A (pt) Derivados de ácido sulfÈnico
BR0313917A (pt) Composições antimicrobianas
BRPI0411841A (pt) cis-2,4,5-triaril-imidazolinas
BR0101230A (pt) Processo para a preparação de11-amino-3-cloro-6,11-diidro-5-5-dioxo-6-metil-dibenzo[c,f][1,2]tiazepina e aplicação para a sìntese detianeptina
BR0115139A (pt) Compostos bis-heterocìclicos com atividade antitumor e quimiossensibilizante
BRPI0411597A (pt) cis-imidazolinas como inibidores de mdm2
BR0317383A (pt) Metabólitos agonista de vasopressina biologicamente ativos
ATE401901T1 (de) Antikrebs- und antivirale zusammensetzung
BR9810433A (pt) Composições anti-helmìnticas
AR029460A1 (es) COMPUESTO DERIVADO DE PIRROLIDINA, COMPOSICIoN FARMACEUTICA QUE LO COMPRENDE Y COMPUESTO INTERMEDIARIO

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUI DADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 9A ANUIDADE.